Role of aldo‐keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential

The role of aldo‐keto reductase family 1 member B1 (AKR1B1) in cancer is not totally clear but growing evidence is suggesting to have a great impact on cancer progression. AKR1B1 could participate in a complicated network of signalling pathways, proteins and miRNAs such as mir‐21 mediating mechanism...

Full description

Saved in:
Bibliographic Details
Published inJournal of cellular and molecular medicine Vol. 24; no. 16; pp. 8890 - 8902
Main Authors Khayami, Reza, Hashemi, Seyyed Reza, Kerachian, Mohammad Amin
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.08.2020
John Wiley and Sons Inc
Subjects
AKR1B1
AKT protein
Aldehyde Reductase - metabolism
aldose reductase
Animals
Antineoplastic Agents - pharmacology
Apoptosis
Binding sites
biomarker
Biomarkers, Tumor - metabolism
Cancer
Cell cycle
Cell survival
Colorectal cancer
Cyclins
DNA methylation
Enzyme Inhibitors - pharmacology
Enzymes
Glucose
Growth factors
Humans
Inflammation
Kinases
Lipid peroxidation
Lipids
Lymphocytes B
Mesenchyme
Metabolism
Metastasis
methylation
Neoplasms - drug therapy
Neoplasms - metabolism
Neoplasms - pathology
NF-κB protein
Proteins
Rapamycin
Reactive oxygen species
Reductase
Review
Reviews
Signal transduction
TOR protein
Tumor necrosis factor-TNF
Tumorigenesis
Tumors
tumour
aldose reductase
AKR1B1
cancer
biomarker
methylation
tumour
Online AccessGet full text

Cover

Abstract The role of aldo‐keto reductase family 1 member B1 (AKR1B1) in cancer is not totally clear but growing evidence is suggesting to have a great impact on cancer progression. AKR1B1 could participate in a complicated network of signalling pathways, proteins and miRNAs such as mir‐21 mediating mechanisms like inflammatory responses, cell cycle, epithelial to mesenchymal transition, cell survival and apoptosis. AKR1B1 has been shown to be mostly overexpressed in cancer. This overexpression has been associated with inflammatory mediators including nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NFκB), cell cycle mediators such as cyclins and cyclin‐dependent kinases (CDKs), survival proteins and pathways like mammalian target of rapamycin (mTOR) and protein kinase B (PKB) or AKT, and other regulatory factors in response to reactive oxygen species (ROS) and prostaglandin synthesis. In addition, inhibition of AKR1B1 has been shown to mostly have anti‐cancer effects. Several studies have also suggested that AKR1B1 inhibition as an adjuvant therapy could render tumour cells more sensitive to anti‐cancer therapy or alleviate the adverse effects of therapy. AKR1B1 could also be considered as a potential cancer diagnostic biomarker since its promoter has shown high levels of methylation. Although pre‐clinical investigations on the role of AKR1B1 in cancer and the application of its inhibitors have shown promising results, the lack of clinical studies on AKR1B1 inhibitors has hampered the use of these drugs to treat cancer. Thus, there is a need to conduct more clinical studies on the application of AKR1B1 inhibitors as adjuvant therapy on different cancers.
AbstractList The role of aldo-keto reductase family 1 member B1 (AKR1B1) in cancer is not totally clear but growing evidence is suggesting to have a great impact on cancer progression. AKR1B1 could participate in a complicated network of signalling pathways, proteins and miRNAs such as mir-21 mediating mechanisms like inflammatory responses, cell cycle, epithelial to mesenchymal transition, cell survival and apoptosis. AKR1B1 has been shown to be mostly overexpressed in cancer. This overexpression has been associated with inflammatory mediators including nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), cell cycle mediators such as cyclins and cyclin-dependent kinases (CDKs), survival proteins and pathways like mammalian target of rapamycin (mTOR) and protein kinase B (PKB) or AKT, and other regulatory factors in response to reactive oxygen species (ROS) and prostaglandin synthesis. In addition, inhibition of AKR1B1 has been shown to mostly have anti-cancer effects. Several studies have also suggested that AKR1B1 inhibition as an adjuvant therapy could render tumour cells more sensitive to anti-cancer therapy or alleviate the adverse effects of therapy. AKR1B1 could also be considered as a potential cancer diagnostic biomarker since its promoter has shown high levels of methylation. Although pre-clinical investigations on the role of AKR1B1 in cancer and the application of its inhibitors have shown promising results, the lack of clinical studies on AKR1B1 inhibitors has hampered the use of these drugs to treat cancer. Thus, there is a need to conduct more clinical studies on the application of AKR1B1 inhibitors as adjuvant therapy on different cancers.
The role of aldo‐keto reductase family 1 member B1 (AKR1B1) in cancer is not totally clear but growing evidence is suggesting to have a great impact on cancer progression. AKR1B1 could participate in a complicated network of signalling pathways, proteins and miRNAs such as mir‐21 mediating mechanisms like inflammatory responses, cell cycle, epithelial to mesenchymal transition, cell survival and apoptosis. AKR1B1 has been shown to be mostly overexpressed in cancer. This overexpression has been associated with inflammatory mediators including nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NFκB), cell cycle mediators such as cyclins and cyclin‐dependent kinases (CDKs), survival proteins and pathways like mammalian target of rapamycin (mTOR) and protein kinase B (PKB) or AKT, and other regulatory factors in response to reactive oxygen species (ROS) and prostaglandin synthesis. In addition, inhibition of AKR1B1 has been shown to mostly have anti‐cancer effects. Several studies have also suggested that AKR1B1 inhibition as an adjuvant therapy could render tumour cells more sensitive to anti‐cancer therapy or alleviate the adverse effects of therapy. AKR1B1 could also be considered as a potential cancer diagnostic biomarker since its promoter has shown high levels of methylation. Although pre‐clinical investigations on the role of AKR1B1 in cancer and the application of its inhibitors have shown promising results, the lack of clinical studies on AKR1B1 inhibitors has hampered the use of these drugs to treat cancer. Thus, there is a need to conduct more clinical studies on the application of AKR1B1 inhibitors as adjuvant therapy on different cancers.
The role of aldo-keto reductase family 1 member B1 (AKR1B1) in cancer is not totally clear but growing evidence is suggesting to have a great impact on cancer progression. AKR1B1 could participate in a complicated network of signalling pathways, proteins and miRNAs such as mir-21 mediating mechanisms like inflammatory responses, cell cycle, epithelial to mesenchymal transition, cell survival and apoptosis. AKR1B1 has been shown to be mostly overexpressed in cancer. This overexpression has been associated with inflammatory mediators including nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), cell cycle mediators such as cyclins and cyclin-dependent kinases (CDKs), survival proteins and pathways like mammalian target of rapamycin (mTOR) and protein kinase B (PKB) or AKT, and other regulatory factors in response to reactive oxygen species (ROS) and prostaglandin synthesis. In addition, inhibition of AKR1B1 has been shown to mostly have anti-cancer effects. Several studies have also suggested that AKR1B1 inhibition as an adjuvant therapy could render tumour cells more sensitive to anti-cancer therapy or alleviate the adverse effects of therapy. AKR1B1 could also be considered as a potential cancer diagnostic biomarker since its promoter has shown high levels of methylation. Although pre-clinical investigations on the role of AKR1B1 in cancer and the application of its inhibitors have shown promising results, the lack of clinical studies on AKR1B1 inhibitors has hampered the use of these drugs to treat cancer. Thus, there is a need to conduct more clinical studies on the application of AKR1B1 inhibitors as adjuvant therapy on different cancers.The role of aldo-keto reductase family 1 member B1 (AKR1B1) in cancer is not totally clear but growing evidence is suggesting to have a great impact on cancer progression. AKR1B1 could participate in a complicated network of signalling pathways, proteins and miRNAs such as mir-21 mediating mechanisms like inflammatory responses, cell cycle, epithelial to mesenchymal transition, cell survival and apoptosis. AKR1B1 has been shown to be mostly overexpressed in cancer. This overexpression has been associated with inflammatory mediators including nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), cell cycle mediators such as cyclins and cyclin-dependent kinases (CDKs), survival proteins and pathways like mammalian target of rapamycin (mTOR) and protein kinase B (PKB) or AKT, and other regulatory factors in response to reactive oxygen species (ROS) and prostaglandin synthesis. In addition, inhibition of AKR1B1 has been shown to mostly have anti-cancer effects. Several studies have also suggested that AKR1B1 inhibition as an adjuvant therapy could render tumour cells more sensitive to anti-cancer therapy or alleviate the adverse effects of therapy. AKR1B1 could also be considered as a potential cancer diagnostic biomarker since its promoter has shown high levels of methylation. Although pre-clinical investigations on the role of AKR1B1 in cancer and the application of its inhibitors have shown promising results, the lack of clinical studies on AKR1B1 inhibitors has hampered the use of these drugs to treat cancer. Thus, there is a need to conduct more clinical studies on the application of AKR1B1 inhibitors as adjuvant therapy on different cancers.
Author Hashemi, Seyyed Reza
Khayami, Reza
Kerachian, Mohammad Amin
AuthorAffiliation 1 Medical Genetics Research Center Mashhad University of Medical Sciences Mashhad Iran
2 Department of Medical Genetics Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran
3 Student Research Committee Mashhad University of Medical Sciences Mashhad Iran
4 Cancer Genetics Research Unit Reza Radiotherapy and Oncology Center Mashhad Iran
AuthorAffiliation_xml – name: 1 Medical Genetics Research Center Mashhad University of Medical Sciences Mashhad Iran
– name: 2 Department of Medical Genetics Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran
– name: 4 Cancer Genetics Research Unit Reza Radiotherapy and Oncology Center Mashhad Iran
– name: 3 Student Research Committee Mashhad University of Medical Sciences Mashhad Iran
Author_xml – sequence: 1
  givenname: Reza
  surname: Khayami
  fullname: Khayami, Reza
  organization: Mashhad University of Medical Sciences
– sequence: 2
  givenname: Seyyed Reza
  surname: Hashemi
  fullname: Hashemi, Seyyed Reza
  organization: Mashhad University of Medical Sciences
– sequence: 3
  givenname: Mohammad Amin
  orcidid: 0000-0001-5016-2882
  surname: Kerachian
  fullname: Kerachian, Mohammad Amin
  email: kerachianma@mums.ac.ir, amin.kerachian@mail.mcgill.ca
  organization: Reza Radiotherapy and Oncology Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32633024$$D View this record in MEDLINE/PubMed
BookMark eNp9ksuKFDEUhoOMOBfd-AAScDMKPeZWlcpGmGm8zyAMug5JKnHSpiplklJ65yP4jD6JabtHdJDJJoHz_f85h_yHYG-MowXgIUYnuJ5nKzMMJ7hpOnwHHOCmIwsmKNvbvXFHu31wmPMKIdpiKu6BfUpaShFhB2C4jMHC6KAKffz5_cdnWyJMtp9NUdlCpwYf1hDDwQ7aJniG4fHpu0t8hp9AP8JyZaFRo6mVKUVjc4Zq7KEveVNKarJz8QZOsdixeBXug7tOhWwf7O4j8PHliw_L14vz96_eLE_PF6ZhBC-4s1irpldWccKV7o3RrUa60bonXIhGMEKZEI45o5nhlKsOOacR1R1pe0ePwPOt7zTrwfamdk8qyCn5QaW1jMrLfyujv5Kf4lfJGeatINXgeGeQ4pfZ5iIHn40NQY02zlmSOiZGXBBW0cc30FWc01jXq1TLO1wd6e0UJUSghnaVevT33H8Gvv6vCqAtYFLMOVknjS-q-LhZwweJkdxEQm4iIX9Hokqe3pBcu_4Xxlv4mw92fQsp3y4vLraaX2YwxxY
CitedBy_id crossref_primary_10_1186_s12944_021_01554_1
crossref_primary_10_1007_s11224_020_01714_6
crossref_primary_10_1016_j_intimp_2023_110145
crossref_primary_10_2174_0929867327666201027152737
crossref_primary_10_1124_dmd_122_001011
crossref_primary_10_1615_CritRevImmunol_2024052391
crossref_primary_10_32604_or_2024_049918
crossref_primary_10_1038_s41598_023_27962_0
crossref_primary_10_3389_fphar_2022_958070
crossref_primary_10_3390_antiox11122347
crossref_primary_10_1093_jrr_rraf010
crossref_primary_10_1016_j_hlife_2023_12_002
crossref_primary_10_1016_j_anireprosci_2024_107567
crossref_primary_10_1016_j_jphs_2021_05_001
crossref_primary_10_1002_cbin_12275
crossref_primary_10_1186_s13148_023_01609_3
crossref_primary_10_3389_fsurg_2023_1088292
crossref_primary_10_1016_j_canlet_2025_217583
crossref_primary_10_1186_s12943_021_01445_0
crossref_primary_10_3390_cimb45040222
crossref_primary_10_1002_jmr_2991
crossref_primary_10_1016_j_ejphar_2022_175191
crossref_primary_10_3390_cells13161311
crossref_primary_10_1186_s12935_020_01627_8
crossref_primary_10_1186_s12967_023_04233_0
crossref_primary_10_3389_fphar_2024_1491249
crossref_primary_10_1016_j_jsps_2021_09_015
crossref_primary_10_1021_acs_jmedchem_2c02089
crossref_primary_10_1097_MD_0000000000030927
crossref_primary_10_2174_1574892817666220511162046
crossref_primary_10_1007_s12274_022_4167_z
crossref_primary_10_1038_s41523_025_00723_0
crossref_primary_10_1177_15593258241282574
crossref_primary_10_1016_j_pbiomolbio_2023_04_002
crossref_primary_10_1177_11795549241290796
crossref_primary_10_3390_cancers14030809
crossref_primary_10_1016_j_intimp_2024_113911
crossref_primary_10_1371_journal_pone_0271602
crossref_primary_10_1080_07391102_2024_2435623
crossref_primary_10_3390_molecules26102867
crossref_primary_10_1002_kjm2_12624
crossref_primary_10_1039_D3CP05985E
crossref_primary_10_3390_ijms24032129
crossref_primary_10_3390_molecules27134194
crossref_primary_10_1089_dna_2022_0644
crossref_primary_10_1016_j_bioorg_2021_105164
crossref_primary_10_1007_s10528_024_10984_2
crossref_primary_10_18632_aging_205041
crossref_primary_10_2147_JHC_S323743
crossref_primary_10_3390_biomedicines9020146
crossref_primary_10_1080_10715762_2023_2243029
crossref_primary_10_3390_cancers13143398
crossref_primary_10_2174_1871520622666220204115151
crossref_primary_10_1186_s13073_022_01089_9
crossref_primary_10_3390_informatics11040095
crossref_primary_10_1002_hsr2_1605
crossref_primary_10_1155_2022_9979200
crossref_primary_10_1186_s13148_025_01811_5
crossref_primary_10_1002_biot_202400163
crossref_primary_10_1016_j_ejmech_2025_117278
crossref_primary_10_1016_j_cancergen_2020_12_007
crossref_primary_10_3390_insects16010038
crossref_primary_10_1016_j_bcp_2023_115528
crossref_primary_10_1021_acsomega_1c05361
Cites_doi 10.4161/epi.29632
10.1042/bj3260625
10.1186/1756-9966-33-4
10.3389/fphys.2014.00272
10.1084/jem.20160903
10.1016/0006-3002(56)90247-5
10.1016/S0006-2952(97)84253-0
10.3390/ijms19092553
10.1074/mcp.M116.062273
10.1016/j.jsbmb.2017.02.015
10.3389/fphar.2013.00013
10.1016/j.mce.2015.07.008
10.1371/journal.pone.0048178
10.18632/oncotarget.25267
10.1111/j.1759-7714.2011.00092.x
10.1155/2016/2192853
10.1016/j.bcp.2018.02.018
10.1093/carcin/bgr102
10.1016/S0009-2797(02)00193-X
10.1158/1535-7163.MCT-09-0795
10.1016/j.cca.2018.11.018
10.1038/s41598-020-59690-0
10.1016/S0021-9258(20)89582-9
10.1002/ptr.5774
10.1007/s00109-008-0393-4
10.1007/s13402-017-0351-7
10.1210/jc.2003-030070
10.1371/journal.pone.0043789
10.1016/j.phrs.2008.05.009
10.1039/C9BM00221A
10.1158/0008-5472.CAN-17-2834
10.1002/hep.20060
10.1016/j.cbi.2014.09.024
10.1016/j.cbi.2011.02.004
10.1002/ijc.2910620617
10.1007/BF00194644
10.1074/jbc.272.26.16431
10.1210/jc.2003-031830
10.1007/s00204-018-2258-0
10.1007/s10456-011-9206-4
10.1097/00001813-200102000-00005
10.1074/mcp.M113.035105
10.1371/journal.pone.0200735
10.1038/s41598-017-03284-w
10.1530/REP-10-0240
10.2174/1568009617666170808105633
10.1016/j.canlet.2007.01.001
10.1074/jbc.M114.610121
10.3892/or.2016.4619
10.1007/s11033-018-4332-3
10.1007/s10585-018-9903-0
10.1016/j.canlet.2007.03.018
10.18632/oncotarget.16343
10.1097/00001813-200209000-00012
10.1186/1471-2407-12-381
10.1007/s12035-014-9035-8
10.1007/s13277-015-4003-0
10.1080/13543776.2019.1582646
10.1007/s00018-005-5024-4
10.1016/j.freeradbiomed.2016.08.015
10.1158/0008-5472.CAN-07-2938
10.1016/j.canlet.2014.09.006
10.1515/bmc.2011.002
10.1134/S0026893310020056
10.1056/NEJMoa1311194
10.1371/journal.pone.0046000
10.3389/fonc.2018.00160
10.1016/j.visres.2017.03.002
10.1016/j.bcp.2019.02.035
10.1111/j.1349-7006.2003.tb01403.x
10.1016/j.bcp.2020.113959
10.1007/s10620-018-4943-5
10.1016/j.toxlet.2012.12.026
10.2174/1871520618666180731093433
10.1016/j.cbi.2012.11.001
10.1186/s13148-015-0110-4
10.1016/S0163-7258(00)00086-3
10.1158/0008-5472.CAN-06-2105
10.1016/j.mce.2009.04.013
10.1016/j.bbapap.2011.05.018
10.1016/j.tibs.2011.03.006
10.1016/j.trsl.2018.02.002
10.1007/s13402-014-0189-1
10.1016/j.lfs.2017.07.015
10.1089/ars.2012.4643
10.1007/s13258-017-0644-2
10.1177/1933719118816836
10.1111/cas.13604
10.2174/156800911795655958
10.1016/j.ejca.2013.05.031
10.1016/j.cbi.2010.12.026
10.1016/j.canlet.2017.09.031
10.1016/S0021-9258(18)82356-0
10.1016/j.bcp.2018.08.001
10.5732/cjc.011.10315
10.1007/s10238-014-0298-1
10.3389/fphar.2012.00104
10.1016/j.breast.2016.11.003
10.18632/oncotarget.8352
10.18632/oncotarget.17791
10.1016/j.cbi.2011.02.023
10.1016/j.redox.2014.12.011
10.1210/jc.82.9.3054
10.2337/diab.29.6.438
10.1155/2017/3904098
10.1016/j.freeradbiomed.2013.05.039
10.1210/jc.82.7.2294
10.1016/j.redox.2013.04.001
ContentType Journal Article
Copyright 2020 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2020 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
– notice: 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
– notice: 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7TK
7X7
7XB
88E
88I
8AO
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
RC3
7X8
5PM
DOI 10.1111/jcmm.15581
DatabaseName Wiley Online Library Journals (Open Access)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection (via ProQuest)
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

CrossRef
MEDLINE

Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate KHAYAMI et al
EISSN 1582-4934
EndPage 8902
ExternalDocumentID PMC7417692
32633024
10_1111_jcmm_15581
JCMM15581
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
0R~
1OC
24P
29K
31~
36B
3V.
4.4
53G
5GY
5VS
7X7
8-0
8-1
88E
88I
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
AAHHS
AAZKR
ABUWG
ACCFJ
ACCMX
ACGFS
ACGOD
ACXQS
ADBBV
ADKYN
ADPDF
ADRAZ
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFBPY
AFKRA
AFZJQ
AHMBA
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
D-9
D-I
DIK
DU5
DWQXO
E3Z
EBD
EBS
EJD
EMB
EMOBN
F5P
FYUFA
GNUQQ
GODZA
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IHR
ITC
KQ8
LH4
LK8
LW6
M1P
M2P
M48
M7P
O9-
OIG
OK1
OVD
OVEED
PIMPY
PQQKQ
PROAC
PSQYO
Q2X
RNS
ROL
RPM
SV3
TEORI
UKHRP
WIN
AAYXX
ABJNI
CITATION
PHGZM
PHGZT
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7QP
7TK
7XB
8FD
8FK
FR3
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
Q9U
RC3
7X8
5PM
ID FETCH-LOGICAL-c5421-7fe1ba5daea727abdccb6b0b5bbd279959423499f4fcb4c737a80ffb03b826df3
IEDL.DBID M48
ISSN 1582-1838
1582-4934
IngestDate Thu Aug 21 14:18:04 EDT 2025
Fri Jul 11 07:24:17 EDT 2025
Wed Aug 13 09:04:54 EDT 2025
Wed Aug 13 11:27:17 EDT 2025
Mon Jul 21 05:56:12 EDT 2025
Tue Jul 01 01:35:10 EDT 2025
Thu Apr 24 22:57:27 EDT 2025
Wed Jan 22 16:34:14 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 16
Keywords aldose reductase
AKR1B1
cancer
biomarker
methylation
tumour
Language English
License Attribution
2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5421-7fe1ba5daea727abdccb6b0b5bbd279959423499f4fcb4c737a80ffb03b826df3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-5016-2882
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1111/jcmm.15581
PMID 32633024
PQID 2432290538
PQPubID 2034150
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7417692
proquest_miscellaneous_2421107924
proquest_journals_2467811763
proquest_journals_2432290538
pubmed_primary_32633024
crossref_citationtrail_10_1111_jcmm_15581
crossref_primary_10_1111_jcmm_15581
wiley_primary_10_1111_jcmm_15581_JCMM15581
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate August 2020
PublicationDateYYYYMMDD 2020-08-01
PublicationDate_xml – month: 08
  year: 2020
  text: August 2020
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Chichester
– name: Hoboken
PublicationTitle Journal of cellular and molecular medicine
PublicationTitleAlternate J Cell Mol Med
PublicationYear 2020
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References 2013; 4
2013; 1
1997; 272
2000; 87
2002; 13
2013; 63
2005; 62
2014; 370
2016; 2016
2011; 191
2018; 40
2020; 10
2018; 45
2019; 163
2012; 12
2016; 37
2016; 35
2018; 9
2018; 8
2015; 413
1997; 54
2004; 39
1991; 86
2019; 26
2014; 13
2019; 29
2020; 177
2010; 9
2018; 35
2019; 7
2011; 2
2008; 58
2018; 109
2016; 16
2017; 411
2012; 31
2017; 139
2016; 99
2018; 197
2010; 44
2018; 19
2018; 18
2016; 7
1997; 326
2013; 218
2015; 234
1956; 22
2018; 92
2014; 37
2011; 1814
2014; 33
2018; 13
2017; 40
2017; 7
2017; 8
1997; 82
2013; 202
2011; 11
1992; 19
2019; 488
2010; 140
2011; 14
2003; 94
2013; 18
2017; 31
1995; 62
2007; 255
2014; 5
2015; 290
1991; 266
2006; 66
2007; 252
1997; 17
2008; 68
2018; 78
2014; 9
2001; 12
2003; 88
2015; 15
2015; 4
1980; 29
2013; 49
2006; 12
2017; 2017
2004; 89
2016; 53
2017; 171
2011; 32
2018; 63
2011; 36
1993; 268
2015; 7
2017; 214
2014; 355
2012; 3
2018; 150
2017; 16
2003; 143–144
2018; 156
2017; 185
2008; 86
2012; 7
2009; 307
2003; 63
e_1_2_11_70_1
e_1_2_11_93_1
e_1_2_11_32_1
e_1_2_11_55_1
e_1_2_11_78_1
e_1_2_11_36_1
e_1_2_11_74_1
e_1_2_11_97_1
e_1_2_11_13_1
e_1_2_11_29_1
e_1_2_11_4_1
e_1_2_11_106_1
e_1_2_11_48_1
Bertherat J (e_1_2_11_72_1) 2003; 63
e_1_2_11_102_1
e_1_2_11_81_1
e_1_2_11_66_1
e_1_2_11_47_1
e_1_2_11_89_1
e_1_2_11_24_1
e_1_2_11_62_1
e_1_2_11_8_1
e_1_2_11_43_1
e_1_2_11_85_1
e_1_2_11_17_1
e_1_2_11_59_1
e_1_2_11_113_1
e_1_2_11_50_1
e_1_2_11_31_1
e_1_2_11_77_1
e_1_2_11_58_1
e_1_2_11_35_1
e_1_2_11_73_1
e_1_2_11_12_1
e_1_2_11_54_1
e_1_2_11_96_1
e_1_2_11_103_1
e_1_2_11_28_1
e_1_2_11_5_1
e_1_2_11_61_1
e_1_2_11_80_1
Saraswat M (e_1_2_11_51_1) 2006; 12
e_1_2_11_46_1
e_1_2_11_69_1
e_1_2_11_88_1
e_1_2_11_107_1
e_1_2_11_9_1
e_1_2_11_23_1
e_1_2_11_42_1
e_1_2_11_65_1
e_1_2_11_84_1
e_1_2_11_114_1
e_1_2_11_16_1
e_1_2_11_110_1
e_1_2_11_39_1
e_1_2_11_91_1
e_1_2_11_30_1
e_1_2_11_57_1
e_1_2_11_99_1
e_1_2_11_34_1
e_1_2_11_53_1
e_1_2_11_76_1
e_1_2_11_11_1
e_1_2_11_6_1
e_1_2_11_104_1
e_1_2_11_27_1
Grewal AS (e_1_2_11_20_1) 2016; 16
Bando T (e_1_2_11_92_1) 1997; 17
e_1_2_11_2_1
e_1_2_11_100_1
Weiss RB (e_1_2_11_95_1) 1992; 19
e_1_2_11_83_1
e_1_2_11_60_1
e_1_2_11_45_1
e_1_2_11_68_1
e_1_2_11_41_1
e_1_2_11_87_1
e_1_2_11_108_1
e_1_2_11_22_1
e_1_2_11_64_1
e_1_2_11_115_1
e_1_2_11_15_1
e_1_2_11_111_1
e_1_2_11_38_1
e_1_2_11_19_1
e_1_2_11_94_1
e_1_2_11_71_1
e_1_2_11_90_1
e_1_2_11_10_1
e_1_2_11_56_1
e_1_2_11_79_1
e_1_2_11_14_1
e_1_2_11_52_1
e_1_2_11_98_1
e_1_2_11_33_1
e_1_2_11_75_1
e_1_2_11_7_1
e_1_2_11_105_1
e_1_2_11_26_1
e_1_2_11_3_1
e_1_2_11_49_1
e_1_2_11_101_1
e_1_2_11_82_1
e_1_2_11_21_1
e_1_2_11_44_1
e_1_2_11_67_1
e_1_2_11_25_1
e_1_2_11_40_1
e_1_2_11_63_1
e_1_2_11_86_1
e_1_2_11_109_1
e_1_2_11_18_1
e_1_2_11_37_1
e_1_2_11_112_1
References_xml – volume: 266
  start-page: 6872
  year: 1991
  end-page: 6877
  article-title: Structure of the human aldose reductase gene
  publication-title: J Biol Chem
– volume: 139
  start-page: 138
  year: 2017
  end-page: 152
  article-title: Diabetic complications in the cornea
  publication-title: Vision Res
– volume: 88
  start-page: 3958
  year: 2003
  end-page: 3965
  article-title: Transcription factor 3',5'‐cyclic adenosine 5'‐monophosphate‐responsive element‐binding protein (creb) is decreased during human adrenal cortex tumorigenesis and fetal development
  publication-title: J Clin Endocrinol Metab
– volume: 18
  start-page: 2042
  year: 2018
  end-page: 2052
  article-title: Gedunin, a neem limonoid in combination with epalrestat inhibits cancer hallmarks by attenuating aldose reductase‐driven oncogenic signaling in scc131 oral cancer cells
  publication-title: Anticancer Agents Med Chem
– volume: 7
  year: 2012
  article-title: Genomic alterations in breast cancer patients in betel quid and non betel quid chewers
  publication-title: PLoS One
– volume: 63
  start-page: 934
  year: 2018
  end-page: 944
  article-title: Aldo‐keto reductases as early biomarkers of hepatocellular carcinoma: A comparison between animal models and human hcc
  publication-title: Dig Dis Sci
– volume: 49
  start-page: 3311
  year: 2013
  end-page: 3319
  article-title: Aldose reductase inhibition suppresses colon cancer cell viability by modulating microrna‐21 mediated programmed cell death 4 (pdcd4) expression
  publication-title: Eur J Cancer
– volume: 53
  start-page: 662
  year: 2016
  end-page: 676
  article-title: Aldose reductase regulates microglia/macrophages polarization through the camp response element‐binding protein after spinal cord injury in mice
  publication-title: Mol Neurobiol
– volume: 268
  start-page: 16052
  year: 1993
  end-page: 16058
  article-title: Characterization of the human aldose reductase gene promoter
  publication-title: J Biol Chem
– volume: 2017
  start-page: 3904098
  year: 2017
  article-title: Adverse health effects of betel quid and the risk of oral and pharyngeal cancers
  publication-title: Biomed Res Int
– volume: 140
  start-page: 885
  year: 2010
  end-page: 892
  article-title: Prostaglandin f2alpha (pgf2alpha) stimulates ptgs2 expression and pgf2alpha synthesis through nfkb activation via reactive oxygen species in the corpus luteum of pseudopregnant rats
  publication-title: Reproduction
– volume: 9
  start-page: 23780
  year: 2018
  end-page: 23823
  article-title: P53 and metabolism: From mechanism to therapeutics
  publication-title: Oncotarget
– volume: 29
  start-page: 438
  year: 1980
  end-page: 449
  article-title: Immunohistochemical localization of aldose reductase. I. Enzyme purification and antibody preparation–localization in peripheral nerve, artery, and testis
  publication-title: Diabetes
– volume: 13
  year: 2018
  article-title: The importance of stool DNA methylation in colorectal cancer diagnosis: A meta‐analysis
  publication-title: PLoS One
– volume: 12
  start-page: Cr525‐9
  year: 2006
  article-title: Overexpression of aldose reductase in human cancer tissues
  publication-title: Med Sci Monit
– volume: 8
  start-page: 66987
  year: 2017
  end-page: 67000
  article-title: Aldose reductase interacts with akt1 to augment hepatic akt/mtor signaling and promote hepatocarcinogenesis
  publication-title: Oncotarget
– volume: 63
  start-page: 5308
  year: 2003
  end-page: 5319
  article-title: Molecular and functional analysis of prkar1a and its locus (17q22‐24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase a expression and activity
  publication-title: Cancer Res
– volume: 413
  start-page: 236
  year: 2015
  end-page: 247
  article-title: 11beta‐prostaglandin f2alpha, a bioactive metabolite catalyzed by akr1c3, stimulates prostaglandin f receptor and induces slug expression in breast cancer
  publication-title: Mol Cell Endocrinol
– volume: 86
  start-page: 1279
  year: 2008
  end-page: 1285
  article-title: Simvastatin activates keap1/nrf2 signaling in rat liver
  publication-title: J Mol Med (Berl)
– volume: 54
  start-page: 639
  year: 1997
  end-page: 647
  article-title: A new nomenclature for the aldo‐keto reductase superfamily
  publication-title: Biochem Pharmacol
– volume: 40
  start-page: 423
  year: 2018
  end-page: 428
  article-title: Bmp3 promoter hypermethylation in plasma‐derived cell‐free DNA in colorectal cancer patients
  publication-title: Genes Genomics
– volume: 191
  start-page: 239
  year: 2011
  end-page: 249
  article-title: Proteasome inhibitors mg‐132 and bortezomib induce akr1c1, akr1c3, akr1b1, and akr1b10 in human colon cancer cell lines sw‐480 and ht‐29
  publication-title: Chem Biol Interact
– volume: 66
  start-page: 9705
  year: 2006
  end-page: 9713
  article-title: Aldose reductase regulates growth factor‐induced cyclooxygenase‐2 expression and prostaglandin e2 production in human colon cancer cells
  publication-title: Cancer Res
– volume: 92
  start-page: 2845
  year: 2018
  end-page: 2857
  article-title: Aldo‐keto reductase 1c3 (akr1c3): A missing piece of the puzzle in the dinaciclib interaction profile
  publication-title: Arch Toxicol
– volume: 370
  start-page: 1287
  year: 2014
  end-page: 1297
  article-title: Multitarget stool DNA testing for colorectal‐cancer screening
  publication-title: N Engl J Med
– volume: 9
  start-page: 1149
  year: 2014
  end-page: 1162
  article-title: Whole genome DNA methylation signature of her2‐positive breast cancer
  publication-title: Epigenetics
– volume: 290
  start-page: 6531
  year: 2015
  end-page: 6545
  article-title: Aldo‐keto reductase 1b15 (akr1b15): A mitochondrial human aldo‐keto reductase with activity toward steroids and 3‐keto‐acyl‐coa conjugates
  publication-title: J Biol Chem
– volume: 191
  start-page: 330
  year: 2011
  end-page: 338
  article-title: Aldose reductase inhibition suppresses oxidative stress‐induced inflammatory disorders
  publication-title: Chem Biol Interact
– volume: 197
  start-page: 43
  year: 2018
  end-page: 56
  article-title: Nf‐kappab pathways in the development and progression of colorectal cancer
  publication-title: Transl Res
– volume: 78
  start-page: 1604
  year: 2018
  end-page: 1618
  article-title: Polyol pathway links glucose metabolism to the aggressiveness of cancer cells
  publication-title: Cancer Res
– volume: 411
  start-page: 57
  year: 2017
  end-page: 63
  article-title: Aldose reductase inhibitor, fidarestat regulates mitochondrial biogenesis via nrf2/ho‐1/ampk pathway in colon cancer cells
  publication-title: Cancer Lett
– volume: 214
  start-page: 1065
  year: 2017
  end-page: 1079
  article-title: Akr1b1 promotes basal‐like breast cancer progression by a positive feedback loop that activates the emt program
  publication-title: J Exp Med
– volume: 82
  start-page: 2294
  year: 1997
  end-page: 2298
  article-title: Aldose reductase gene expression is increased in diabetic nephropathy
  publication-title: J Clin Endocrinol Metab
– volume: 44
  start-page: 243
  year: 2010
  end-page: 250
  article-title: downregulation of akr1b10 gene expression in colorectal cancer
  publication-title: Mol Biol (Mosk)
– volume: 37
  start-page: 297
  year: 2014
  end-page: 303
  article-title: Validation of DNA promoter hypermethylation biomarkers in breast cancer–a short report
  publication-title: Cell Oncol (Dordr)
– volume: 89
  start-page: 3010
  year: 2004
  end-page: 3019
  article-title: Decreased expression of cyclic adenosine monophosphate‐regulated aldose reductase (akr1b1) is associated with malignancy in human sporadic adrenocortical tumors
  publication-title: J Clin Endocrinol Metab
– volume: 8
  start-page: 37377
  year: 2017
  end-page: 37393
  article-title: Nfkb is essential for activin‐induced colorectal cancer migration via upregulation of pi3k‐mdm2 pathway
  publication-title: Oncotarget
– volume: 171
  start-page: 43
  year: 2017
  end-page: 53
  article-title: Star and akr1b10 are down‐regulated in high‐grade endometrial cancer
  publication-title: J Steroid Biochem Mol Biol
– volume: 7
  start-page: 74
  year: 2015
  article-title: Epigenetics override pro‐inflammatory ptgs transcriptomic signature towards selective hyperactivation of pge2 in colorectal cancer
  publication-title: Clin Epigenetics
– volume: 5
  start-page: 272
  year: 2014
  article-title: Expression of the prostaglandin f synthase akr1b1 and the prostaglandin transporter slco2a1 in human fetal membranes in relation to spontaneous term and preterm labor
  publication-title: Front Physiol
– volume: 14
  start-page: 209
  year: 2011
  end-page: 221
  article-title: Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo
  publication-title: Angiogenesis
– volume: 68
  start-page: 3645
  year: 2008
  end-page: 3654
  article-title: Loss of e‐cadherin promotes metastasis via multiple downstream transcriptional pathways
  publication-title: Cancer Res
– volume: 87
  start-page: 227
  year: 2000
  end-page: 253
  article-title: Basis for effective combination cancer chemotherapy with antimetabolites
  publication-title: Pharmacol Ther
– volume: 35
  start-page: 2228
  year: 2016
  end-page: 2236
  article-title: Genome‐wide DNA methylation analysis in hepatocellular carcinoma
  publication-title: Oncol Rep
– volume: 17
  start-page: 3345
  year: 1997
  end-page: 3348
  article-title: Exposure to sorbitol induces resistance to cisplatin in human non‐small‐cell lung cancer cell lines
  publication-title: Anticancer Res
– volume: 32
  start-page: 1259
  year: 2011
  end-page: 1267
  article-title: Inhibition of aldose reductase prevents colon cancer metastasis
  publication-title: Carcinogenesis
– volume: 8
  start-page: 160
  year: 2018
  article-title: Phosphoinositide 3‐kinase/akt signaling and redox metabolism in cancer
  publication-title: Front Oncol
– volume: 4
  start-page: 13
  year: 2013
  article-title: Modulators of hif1alpha and nfkb in cancer treatment: Is it a rational approach for controlling malignant progression?
  publication-title: Front Pharmacol
– volume: 12
  start-page: 129
  year: 2001
  end-page: 132
  article-title: Overexpression of aldose reductase in liver cancers may contribute to drug resistance
  publication-title: Anticancer Drugs
– volume: 272
  start-page: 16431
  year: 1997
  end-page: 16437
  article-title: Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene
  publication-title: J Biol Chem
– volume: 13
  start-page: 859
  year: 2002
  end-page: 868
  article-title: Inhibition of aldose reductase enhances hela cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal‐regulated kinases
  publication-title: Anticancer Drugs
– volume: 62
  start-page: 749
  year: 1995
  end-page: 754
  article-title: Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: Implication in detoxification of cytotoxic aldehydes
  publication-title: Int J Cancer
– volume: 12
  start-page: 381
  year: 2012
  article-title: Role of aldo‐keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization
  publication-title: BMC Cancer
– volume: 86
  start-page: 509
  year: 1991
  end-page: 514
  article-title: The human aldose reductase gene maps to chromosome region 7q35
  publication-title: Hum Genet
– volume: 31
  start-page: 137
  year: 2017
  end-page: 143
  article-title: Overexpression and enhanced specific activity of aldoketo reductases (akr1b1 & akr1b10) in human breast cancers
  publication-title: Breast (Edinburgh, Scotland)
– volume: 355
  start-page: 141
  year: 2014
  end-page: 147
  article-title: Aldose reductase inhibition suppresses azoxymethane‐induced colonic premalignant lesions in c57bl/ksj‐db/db mice
  publication-title: Cancer Lett
– volume: 99
  start-page: 323
  year: 2016
  end-page: 332
  article-title: Human carbonyl reductase 1 as efficient catalyst for the reduction of glutathionylated aldehydes derived from lipid peroxidation
  publication-title: Free Radic Biol Med
– volume: 19
  start-page: 2553
  year: 2018
  article-title: DNA methylation profiling of breast cancer cell lines along the epithelial mesenchymal spectrum‐implications for the choice of circulating tumour DNA methylation markers
  publication-title: Int J Mol Sci
– volume: 26
  start-page: 184
  year: 2019
  end-page: 197
  article-title: Ulipristal acetate mediates decreased proteoglycan expression through regulation of nuclear factor of activated t‐cells (nfat5)
  publication-title: Reprod Sci
– volume: 9
  start-page: 813
  year: 2010
  end-page: 824
  article-title: Inhibition of aldose reductase prevents growth factor‐induced g1‐s phase transition through the akt/phosphoinositide 3‐kinase/e2f‐1 pathway in human colon cancer cells
  publication-title: Mol Cancer Ther
– volume: 185
  start-page: 73
  year: 2017
  end-page: 84
  article-title: Molecular docking prediction and in vitro studies elucidate anti‐cancer activity of phytoestrogens
  publication-title: Life Sci
– volume: 7
  start-page: 2889
  year: 2019
  end-page: 2906
  article-title: Targeted co‐delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox‐sensitive prodrug approach promotes synergistic tumor suppression
  publication-title: Biomater Sci
– volume: 39
  start-page: 540
  year: 2004
  end-page: 549
  article-title: Detection and identification of tumor‐associated protein variants in human hepatocellular carcinomas
  publication-title: Hepatology
– volume: 11
  start-page: 560
  year: 2011
  end-page: 571
  article-title: Targeting aldose reductase for the treatment of cancer
  publication-title: Curr Cancer Drug Targets
– volume: 94
  start-page: 1074
  year: 2003
  end-page: 1082
  article-title: Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines
  publication-title: Cancer Sci
– volume: 177
  start-page: 113959
  year: 2020
  article-title: Drug uptake‐based chemoresistance in breast cancer treatment
  publication-title: Biochem Pharmacol
– volume: 234
  start-page: 236
  year: 2015
  end-page: 246
  article-title: The aldo‐keto reductases (akrs): Overview
  publication-title: Chem Biol Interact
– volume: 16
  start-page: 20
  issue: 120–62
  year: 2016
  article-title: Updates on aldose reductase inhibitors for management of diabetic complications and non‐diabetic diseases
  publication-title: Mini Rev Med Chem
– volume: 3
  start-page: 207
  year: 2012
  end-page: 216
  article-title: Screening and identification of lung cancer metastasis‐related genes by suppression subtractive hybridization
  publication-title: Thoracic cancer
– volume: 191
  start-page: 192
  year: 2011
  end-page: 198
  article-title: Human aldo‐keto reductases 1b1 and 1b10: A comparative study on their enzyme activity toward electrophilic carbonyl compounds
  publication-title: Chem Biol Interact
– volume: 15
  start-page: 333
  year: 2015
  end-page: 341
  article-title: Expression of akr1c3 and cnn3 as markers for detection of lymph node metastases in colorectal cancer
  publication-title: Clin Exp Med
– volume: 2016
  start-page: 2192853
  year: 2016
  article-title: Discovery and validation of hypermethylated markers for colorectal cancer
  publication-title: Dis Markers
– volume: 10
  start-page: 2813
  year: 2020
  article-title: Crosstalk between DNA methylation and gene expression in colorectal cancer, a potential plasma biomarker for tracing this tumor
  publication-title: Sci Rep
– volume: 156
  start-page: 22
  year: 2018
  end-page: 31
  article-title: Roscovitine and purvalanol a effectively reverse anthracycline resistance mediated by the activity of aldo‐keto reductase 1c3 (akr1c3): A promising therapeutic target for cancer treatment
  publication-title: Biochem Pharmacol
– volume: 218
  start-page: 39
  year: 2013
  end-page: 49
  article-title: Identification of aldo‐keto reductases as nrf2‐target marker genes in human cells
  publication-title: Toxicol Lett
– volume: 16
  start-page: 407
  year: 2017
  end-page: 427
  article-title: Targeted proteomics for multiplexed verification of markers of colorectal tumorigenesis
  publication-title: Mol Cell Proteomics
– volume: 3
  start-page: 104
  year: 2012
  article-title: Expression of the aldo‐ketoreductases akr1b1 and akr1b10 in human cancers
  publication-title: Front Pharmacol
– volume: 82
  start-page: 3054
  year: 1997
  end-page: 3058
  article-title: Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: Implications for tumorigenesis
  publication-title: J Clin Endocrinol Metab
– volume: 62
  start-page: 1146
  year: 2005
  end-page: 1155
  article-title: Phorbol ester up‐regulates aldose reductase expression in a549 cells: A potential role for aldose reductase in cell cycle modulation
  publication-title: Cell Mol Life Sci
– volume: 4
  start-page: 193
  year: 2015
  end-page: 199
  article-title: Role of lipid peroxidation derived 4‐hydroxynonenal (4‐hne) in cancer: Focusing on mitochondria
  publication-title: Redox Biol
– volume: 29
  start-page: 199
  year: 2019
  end-page: 213
  article-title: Aldose reductase inhibitors: 2013‐present
  publication-title: Expert Opin Ther Pat
– volume: 488
  start-page: 209
  year: 2019
  end-page: 214
  article-title: Long interspersed nucleotide element‐1 (line‐1) methylation in colorectal cancer
  publication-title: Clin Chim Acta
– volume: 1
  start-page: 319
  year: 2013
  end-page: 331
  article-title: Effects of 4‐hydroxynonenal on vascular endothelial and smooth muscle cell redox signaling and function in health and disease
  publication-title: Redox Biol
– volume: 7
  year: 2012
  article-title: Significance of heterogeneous twist2 expression in human breast cancers
  publication-title: PLoS One
– volume: 45
  start-page: 1863
  year: 2018
  end-page: 1871
  article-title: Beta2‐ar regulates the expression of akr1b1 in human pancreatic cancer cells and promotes their proliferation via the erk1/2 pathway
  publication-title: Mol Biol Rep
– volume: 40
  start-page: 563
  year: 2017
  end-page: 578
  article-title: Opposing roles of the aldo‐keto reductases akr1b1 and akr1b10 in colorectal cancer
  publication-title: Cell Oncol (Dordr)
– volume: 36
  start-page: 320
  year: 2011
  end-page: 328
  article-title: The ras‐erk and pi3k‐mtor pathways: Cross‐talk and compensation
  publication-title: Trends Biochem Sci
– volume: 2
  start-page: 103
  year: 2011
  end-page: 114
  article-title: Aldose reductase: New insights for an old enzyme
  publication-title: Biomol Concepts
– volume: 7
  start-page: 24778
  year: 2016
  end-page: 24791
  article-title: DNA promoter hypermethylation in nipple fluid: A potential tool for early breast cancer detection
  publication-title: Oncotarget
– volume: 109
  start-page: 1970
  year: 2018
  end-page: 1980
  article-title: Aldo‐keto reductases‐mediated cytotoxicity of 2‐deoxyglucose: A novel anticancer mechanism
  publication-title: Cancer Sci
– volume: 19
  start-page: 670
  year: 1992
  end-page: 686
  article-title: The anthracyclines: Will we ever find a better doxorubicin?
  publication-title: Semin Oncol
– volume: 143–144
  start-page: 621
  year: 2003
  end-page: 631
  article-title: The aldo‐keto reductase superfamily homepage
  publication-title: Chem Biol Interact
– volume: 22
  start-page: 202
  year: 1956
  end-page: 203
  article-title: the mechanism of the transformation of glucose in fructose in the seminal vesicles
  publication-title: Biochim Biophys Acta
– volume: 31
  start-page: 488
  year: 2017
  end-page: 496
  article-title: Artichoke leaf extract inhibits akr1b1 and reduces nf‐kappab activity in human leukemic cells
  publication-title: Phytother Res
– volume: 307
  start-page: 109
  year: 2009
  end-page: 117
  article-title: Regulation of akr1b1 by thyroid hormone and its receptors
  publication-title: Mol Cell Endocrinol
– volume: 255
  start-page: 49
  year: 2007
  end-page: 56
  article-title: Increased resistance of tumor cells to daunorubicin after transfection of cdnas coding for anthracycline inactivating enzymes
  publication-title: Cancer Lett
– volume: 18
  start-page: 905
  year: 2018
  end-page: 911
  article-title: Aldose reductase inhibitor, fidarestat prevents high‐fat diet‐induced intestinal polyps in apc(min/+) mice
  publication-title: Curr Cancer Drug Targets
– volume: 7
  start-page: 3182
  year: 2017
  article-title: Aldose reductase inhibitor increases doxorubicin‐sensitivity of colon cancer cells and decreases cardiotoxicity
  publication-title: Sci Rep
– volume: 35
  start-page: 309
  year: 2018
  end-page: 318
  article-title: The challenge of drug resistance in cancer treatment: A current overview
  publication-title: Clin Exp Metastasis
– volume: 326
  start-page: 625
  issue: Pt 3
  year: 1997
  end-page: 636
  article-title: Comparative anatomy of the aldo‐keto reductase superfamily
  publication-title: Biochem J
– volume: 63
  start-page: 280
  year: 2013
  end-page: 290
  article-title: Aldose reductase inhibition enhances trail‐induced human colon cancer cell apoptosis through akt/foxo3a‐dependent upregulation of death receptors
  publication-title: Free Radic Biol Med
– volume: 163
  start-page: 290
  year: 2019
  end-page: 298
  article-title: Cyclin‐dependent kinase inhibitors azd5438 and r547 show potential for enhancing efficacy of daunorubicin‐based anticancer therapy: Interaction with carbonyl‐reducing enzymes and abc transporters
  publication-title: Biochem Pharmacol
– volume: 33
  start-page: 4
  year: 2014
  article-title: Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer
  publication-title: J Exp Clin Cancer Res
– volume: 58
  start-page: 15
  year: 2008
  end-page: 21
  article-title: Nrf2 regulates curcumin‐induced aldose reductase expression indirectly via nuclear factor‐kappab
  publication-title: Pharmacol Res
– volume: 13
  start-page: 1198
  year: 2014
  end-page: 1218
  article-title: Sorbitol dehydrogenase overexpression and other aspects of dysregulated protein expression in human precancerous colorectal neoplasms: A quantitative proteomics study
  publication-title: Mol Cell Proteomics
– volume: 202
  start-page: 226
  year: 2013
  end-page: 233
  article-title: Decreased levels of akr1b1 and akr1b10 in cancerous endometrium compared to adjacent non‐cancerous tissue
  publication-title: Chem Biol Interact
– volume: 31
  start-page: 126
  year: 2012
  end-page: 133
  article-title: Reversing multidrug resistance by tyrosine kinase inhibitors
  publication-title: Chin J Cancer
– volume: 7
  year: 2012
  article-title: Detection of methylated sept9 in plasma is a reliable screening method for both left‐ and right‐sided colon cancers
  publication-title: PLoS One
– volume: 252
  start-page: 299
  year: 2007
  end-page: 306
  article-title: Aldose reductase regulates tnf‐alpha‐induced pge2 production in human colon cancer cells
  publication-title: Cancer Lett
– volume: 1814
  start-page: 1367
  year: 2011
  end-page: 1376
  article-title: Gel‐based proteomics of liver cancer progression in rat
  publication-title: Biochim Biophys Acta
– volume: 18
  start-page: 1249
  year: 2013
  end-page: 1262
  article-title: Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of mir‐21 and foxo3a
  publication-title: Antioxid Redox Signal
– volume: 150
  start-page: 181
  year: 2018
  end-page: 190
  article-title: Aldose reductase inhibitor, fidarestat prevents doxorubicin‐induced endothelial cell death and dysfunction
  publication-title: Biochem Pharmacol
– volume: 37
  start-page: 2083
  year: 2016
  end-page: 2093
  article-title: Gedunin abrogates aldose reductase, pi3k/akt/mtor, and nf‐kappab signaling pathways to inhibit angiogenesis in a hamster model of oral carcinogenesis
  publication-title: Tumour Biol
– ident: e_1_2_11_85_1
  doi: 10.4161/epi.29632
– ident: e_1_2_11_3_1
  doi: 10.1042/bj3260625
– ident: e_1_2_11_82_1
  doi: 10.1186/1756-9966-33-4
– volume: 12
  start-page: Cr525‐9
  year: 2006
  ident: e_1_2_11_51_1
  article-title: Overexpression of aldose reductase in human cancer tissues
  publication-title: Med Sci Monit
– ident: e_1_2_11_13_1
  doi: 10.3389/fphys.2014.00272
– ident: e_1_2_11_52_1
  doi: 10.1084/jem.20160903
– ident: e_1_2_11_17_1
  doi: 10.1016/0006-3002(56)90247-5
– ident: e_1_2_11_2_1
  doi: 10.1016/S0006-2952(97)84253-0
– ident: e_1_2_11_86_1
  doi: 10.3390/ijms19092553
– ident: e_1_2_11_36_1
  doi: 10.1074/mcp.M116.062273
– ident: e_1_2_11_69_1
  doi: 10.1016/j.jsbmb.2017.02.015
– volume: 16
  start-page: 20
  issue: 120
  year: 2016
  ident: e_1_2_11_20_1
  article-title: Updates on aldose reductase inhibitors for management of diabetic complications and non‐diabetic diseases
  publication-title: Mini Rev Med Chem
– ident: e_1_2_11_27_1
  doi: 10.3389/fphar.2013.00013
– ident: e_1_2_11_54_1
  doi: 10.1016/j.mce.2015.07.008
– ident: e_1_2_11_57_1
  doi: 10.1371/journal.pone.0048178
– ident: e_1_2_11_49_1
  doi: 10.18632/oncotarget.25267
– ident: e_1_2_11_61_1
  doi: 10.1111/j.1759-7714.2011.00092.x
– ident: e_1_2_11_84_1
  doi: 10.1155/2016/2192853
– ident: e_1_2_11_109_1
  doi: 10.1016/j.bcp.2018.02.018
– ident: e_1_2_11_41_1
  doi: 10.1093/carcin/bgr102
– ident: e_1_2_11_6_1
  doi: 10.1016/S0009-2797(02)00193-X
– ident: e_1_2_11_44_1
  doi: 10.1158/1535-7163.MCT-09-0795
– ident: e_1_2_11_81_1
  doi: 10.1016/j.cca.2018.11.018
– ident: e_1_2_11_80_1
  doi: 10.1038/s41598-020-59690-0
– ident: e_1_2_11_8_1
  doi: 10.1016/S0021-9258(20)89582-9
– ident: e_1_2_11_114_1
  doi: 10.1002/ptr.5774
– ident: e_1_2_11_108_1
  doi: 10.1007/s00109-008-0393-4
– ident: e_1_2_11_30_1
  doi: 10.1007/s13402-017-0351-7
– ident: e_1_2_11_70_1
  doi: 10.1210/jc.2003-030070
– ident: e_1_2_11_56_1
  doi: 10.1371/journal.pone.0043789
– ident: e_1_2_11_14_1
  doi: 10.1016/j.phrs.2008.05.009
– ident: e_1_2_11_102_1
  doi: 10.1039/C9BM00221A
– ident: e_1_2_11_31_1
  doi: 10.1158/0008-5472.CAN-17-2834
– ident: e_1_2_11_64_1
  doi: 10.1002/hep.20060
– ident: e_1_2_11_4_1
  doi: 10.1016/j.cbi.2014.09.024
– ident: e_1_2_11_22_1
  doi: 10.1016/j.cbi.2011.02.004
– ident: e_1_2_11_63_1
  doi: 10.1002/ijc.2910620617
– ident: e_1_2_11_7_1
  doi: 10.1007/BF00194644
– ident: e_1_2_11_10_1
  doi: 10.1074/jbc.272.26.16431
– ident: e_1_2_11_15_1
  doi: 10.1210/jc.2003-031830
– ident: e_1_2_11_103_1
  doi: 10.1007/s00204-018-2258-0
– ident: e_1_2_11_110_1
  doi: 10.1007/s10456-011-9206-4
– ident: e_1_2_11_94_1
  doi: 10.1097/00001813-200102000-00005
– ident: e_1_2_11_32_1
  doi: 10.1074/mcp.M113.035105
– ident: e_1_2_11_78_1
  doi: 10.1371/journal.pone.0200735
– ident: e_1_2_11_101_1
  doi: 10.1038/s41598-017-03284-w
– ident: e_1_2_11_29_1
  doi: 10.1530/REP-10-0240
– ident: e_1_2_11_39_1
  doi: 10.2174/1568009617666170808105633
– ident: e_1_2_11_42_1
  doi: 10.1016/j.canlet.2007.01.001
– ident: e_1_2_11_5_1
  doi: 10.1074/jbc.M114.610121
– ident: e_1_2_11_67_1
  doi: 10.3892/or.2016.4619
– ident: e_1_2_11_59_1
  doi: 10.1007/s11033-018-4332-3
– ident: e_1_2_11_91_1
  doi: 10.1007/s10585-018-9903-0
– ident: e_1_2_11_93_1
  doi: 10.1016/j.canlet.2007.03.018
– ident: e_1_2_11_26_1
  doi: 10.18632/oncotarget.16343
– ident: e_1_2_11_96_1
  doi: 10.1097/00001813-200209000-00012
– ident: e_1_2_11_97_1
  doi: 10.1186/1471-2407-12-381
– ident: e_1_2_11_73_1
  doi: 10.1007/s12035-014-9035-8
– ident: e_1_2_11_112_1
  doi: 10.1007/s13277-015-4003-0
– ident: e_1_2_11_107_1
  doi: 10.1080/13543776.2019.1582646
– ident: e_1_2_11_62_1
  doi: 10.1007/s00018-005-5024-4
– ident: e_1_2_11_23_1
  doi: 10.1016/j.freeradbiomed.2016.08.015
– ident: e_1_2_11_58_1
  doi: 10.1158/0008-5472.CAN-07-2938
– ident: e_1_2_11_40_1
  doi: 10.1016/j.canlet.2014.09.006
– ident: e_1_2_11_21_1
  doi: 10.1515/bmc.2011.002
– ident: e_1_2_11_35_1
  doi: 10.1134/S0026893310020056
– ident: e_1_2_11_79_1
  doi: 10.1056/NEJMoa1311194
– ident: e_1_2_11_76_1
  doi: 10.1371/journal.pone.0046000
– ident: e_1_2_11_43_1
  doi: 10.3389/fonc.2018.00160
– ident: e_1_2_11_19_1
  doi: 10.1016/j.visres.2017.03.002
– ident: e_1_2_11_105_1
  doi: 10.1016/j.bcp.2019.02.035
– ident: e_1_2_11_33_1
  doi: 10.1111/j.1349-7006.2003.tb01403.x
– ident: e_1_2_11_98_1
  doi: 10.1016/j.bcp.2020.113959
– ident: e_1_2_11_65_1
  doi: 10.1007/s10620-018-4943-5
– ident: e_1_2_11_68_1
  doi: 10.1016/j.toxlet.2012.12.026
– ident: e_1_2_11_111_1
  doi: 10.2174/1871520618666180731093433
– volume: 17
  start-page: 3345
  year: 1997
  ident: e_1_2_11_92_1
  article-title: Exposure to sorbitol induces resistance to cisplatin in human non‐small‐cell lung cancer cell lines
  publication-title: Anticancer Res
– ident: e_1_2_11_24_1
  doi: 10.1016/j.cbi.2012.11.001
– ident: e_1_2_11_83_1
  doi: 10.1186/s13148-015-0110-4
– ident: e_1_2_11_99_1
  doi: 10.1016/S0163-7258(00)00086-3
– ident: e_1_2_11_25_1
  doi: 10.1158/0008-5472.CAN-06-2105
– ident: e_1_2_11_11_1
  doi: 10.1016/j.mce.2009.04.013
– ident: e_1_2_11_89_1
  doi: 10.1016/j.bbapap.2011.05.018
– volume: 19
  start-page: 670
  year: 1992
  ident: e_1_2_11_95_1
  article-title: The anthracyclines: Will we ever find a better doxorubicin?
  publication-title: Semin Oncol
– ident: e_1_2_11_50_1
  doi: 10.1016/j.tibs.2011.03.006
– volume: 63
  start-page: 5308
  year: 2003
  ident: e_1_2_11_72_1
  article-title: Molecular and functional analysis of prkar1a and its locus (17q22‐24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase a expression and activity
  publication-title: Cancer Res
– ident: e_1_2_11_28_1
  doi: 10.1016/j.trsl.2018.02.002
– ident: e_1_2_11_87_1
  doi: 10.1007/s13402-014-0189-1
– ident: e_1_2_11_113_1
  doi: 10.1016/j.lfs.2017.07.015
– ident: e_1_2_11_47_1
  doi: 10.1089/ars.2012.4643
– ident: e_1_2_11_77_1
  doi: 10.1007/s13258-017-0644-2
– ident: e_1_2_11_115_1
  doi: 10.1177/1933719118816836
– ident: e_1_2_11_18_1
  doi: 10.1111/cas.13604
– ident: e_1_2_11_106_1
– ident: e_1_2_11_90_1
  doi: 10.2174/156800911795655958
– ident: e_1_2_11_45_1
  doi: 10.1016/j.ejca.2013.05.031
– ident: e_1_2_11_34_1
  doi: 10.1016/j.cbi.2010.12.026
– ident: e_1_2_11_48_1
  doi: 10.1016/j.canlet.2017.09.031
– ident: e_1_2_11_9_1
  doi: 10.1016/S0021-9258(18)82356-0
– ident: e_1_2_11_104_1
  doi: 10.1016/j.bcp.2018.08.001
– ident: e_1_2_11_100_1
  doi: 10.5732/cjc.011.10315
– ident: e_1_2_11_37_1
  doi: 10.1007/s10238-014-0298-1
– ident: e_1_2_11_60_1
  doi: 10.3389/fphar.2012.00104
– ident: e_1_2_11_53_1
  doi: 10.1016/j.breast.2016.11.003
– ident: e_1_2_11_88_1
  doi: 10.18632/oncotarget.8352
– ident: e_1_2_11_66_1
  doi: 10.18632/oncotarget.17791
– ident: e_1_2_11_38_1
  doi: 10.1016/j.cbi.2011.02.023
– ident: e_1_2_11_75_1
  doi: 10.1016/j.redox.2014.12.011
– ident: e_1_2_11_71_1
  doi: 10.1210/jc.82.9.3054
– ident: e_1_2_11_12_1
  doi: 10.2337/diab.29.6.438
– ident: e_1_2_11_55_1
  doi: 10.1155/2017/3904098
– ident: e_1_2_11_46_1
  doi: 10.1016/j.freeradbiomed.2013.05.039
– ident: e_1_2_11_16_1
  doi: 10.1210/jc.82.7.2294
– ident: e_1_2_11_74_1
  doi: 10.1016/j.redox.2013.04.001
SSID ssj0036139
Score 2.5457745
SecondaryResourceType review_article
Snippet The role of aldo‐keto reductase family 1 member B1 (AKR1B1) in cancer is not totally clear but growing evidence is suggesting to have a great impact on cancer...
The role of aldo-keto reductase family 1 member B1 (AKR1B1) in cancer is not totally clear but growing evidence is suggesting to have a great impact on cancer...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 8890
SubjectTerms AKR1B1
AKT protein
Aldehyde Reductase - metabolism
aldose reductase
Animals
Antineoplastic Agents - pharmacology
Apoptosis
Binding sites
biomarker
Biomarkers, Tumor - metabolism
Cancer
Cell cycle
Cell survival
Colorectal cancer
Cyclins
DNA methylation
Enzyme Inhibitors - pharmacology
Enzymes
Glucose
Growth factors
Humans
Inflammation
Kinases
Lipid peroxidation
Lipids
Lymphocytes B
Mesenchyme
Metabolism
Metastasis
methylation
Neoplasms - drug therapy
Neoplasms - metabolism
Neoplasms - pathology
NF-κB protein
Proteins
Rapamycin
Reactive oxygen species
Reductase
Review
Reviews
Signal transduction
TOR protein
Tumor necrosis factor-TNF
Tumorigenesis
Tumors
tumour
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELWgCIkL4pstBQ2CA0UKxB-JNyfUVlRV0XKoqLS3yHZsddXdZNlND_33zDjZ0FWht0SeQ2KPPe_Z4zeMfTRIfFKvQsJVSBNllU-Mw9fCCy8zPnZK0G3kyc_85FydTrNpv-G27tMqN2tiXKirxtEe-VehJEmT4_z8tvydUNUoOl3tS2jcZw9Iuoy8Wk8HwiUxVBW9JGnM3nGLxReMn2O-HYRuIcvbCZI3gWuMPMdP2OMeMsJBN8ZP2T1fP2MPuyKS18_Z5Vkz99AEMPOqSS5928CK9FhbjE_Q7V8Ah4Wnyh9wyOHTwY8zfsj3YVYDoj9wNO4rWHY3BsDUFczaNdy4mAXLpqWkIjN_wc6Pv_86Okn6EgqJy5TgiQ6eW5NVxhsEKsZWztncpjazthKkBVcgnELSE1RwVjkttRmnIdhUWuQdVZAv2U7d1P41A1F4LXxldeGQVbnKKps67UPKbSaVEyO2v-nT0vX64lTmYl4OPAP7v4z9P2IfBttlp6rxT6u9zdCU_cxal3_94D_Nebw7m8sRez8045ShcxBT--aKbCLrReY5Yq-6gR6-AtGslCm16C0XGAxIjnu7pZ5dRFluxGY6L7AfPkdnuePHytOjySQ-7d79i2_YI0H8PiYc7rGddnXl3yIIau276Ol_AKmjCBc
  priority: 102
  providerName: ProQuest
– databaseName: Wiley Online Library Journals (Open Access)
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NatwwEBYhodBLadK_bdMypT00BRfrx_YaeklCQkjZUkIDuRlJlsjSXXvZdQ655RHyjHmSzshes0vSQG82GoOtmdF8I898YuyzxsQndspHXPk4Uka5SFu8zZ1wMuFDqwR1I49-pifn6vQiudhg35e9MC0_RL_hRp4R1mtycG0Wq05up9NvGA2p73qLemupoE-oX8t1WGKgygNbKmJINNxhR04a6nj6Z9fD0T2Meb9UchXChhh0_Jw968Aj7Lfa3mYbrtphT9rjJK9fsOlZPXFQe9CTsr67uf3jmhrmxM3aYKyCdi8DOEwdnQICBxy-7P844wd8D8YVIBIESzYwh1nbPQC6KmHcLGClSQtmdUMFRnrykp0fH_0-PIm64xQimyjBo8w7bnRSaqcRtGhTWmtSE5vEmFIQL1yO0AoTIK-8NcpmMtPD2HsTS4M5SOnlK7ZZ1ZV7w0DkLhOuNFluMcOypVEmtpnzMTeJVFYM2N5yVgvbcY3TkReTos85UANF0MCAfeplZy3DxoNSu0vlFJ2XLQqhJNHV45r9j-E09NGmcsA-9sPoPvRPRFeuviKZkAFjFjpgr1tV92-ByFbKmEayNSPoBYiae32kGl8Gim7EaVma4zx8DebyyIcVp4ejUbh6-z_C79hTQZl_KEXcZZvN_Mq9R3jUmA_BC_4CsCcM8A
  priority: 102
  providerName: Wiley-Blackwell
Title Role of aldo‐keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjcmm.15581
https://www.ncbi.nlm.nih.gov/pubmed/32633024
https://www.proquest.com/docview/2432290538
https://www.proquest.com/docview/2467811763
https://www.proquest.com/docview/2421107924
https://pubmed.ncbi.nlm.nih.gov/PMC7417692
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZpQqGX0vSVbZNFpT00BQfrYWt9KGU3JISUDWGpy9KLkWSJLvXa240DzS0_Ib-xv6Qj2WuyJC304gcag60Zeb6RNN8g9E5C4BMabgPCbRhwxU0gNdwmhhoWkYHm1GUjj8_ik5SfTqPpBlrV72w78OLe0M7Vk0qXxcGvn1efYMB_7Hbl6Pn8APyiy8DeAo8kXCWDMe9WExi4rMTzpgKaBBMetDSl68-uO6Y7aPPupsnbYNZ7o-Mn6HELI_Gw0fs22jDlU_SwKSx59QzNJ1VhcGWxLPLq9_XND1NXeOlYWmvwWriZ1cAEz42rB4JHBL8ffp6QEdnHsxIDJsTaWcMSL5o8AizLHM_qC3wrXQsvqtptNZLFc5QeH305PAnawgqBjjglgbCGKBnl0kiAL1LlWqtYhSpSKqeOIS4BkAWhkOVWK64FE3IQWqtCpiAayS17gTbLqjQ7CNPECGpyJRINsZbOFVehFsaGREWMa9pD-6tezXTLOu6KXxRZF32ABjKvgR5628kuGq6Ne6V2V8rJVuaSUc4ccT38vf_SHPuM2pj10JuuGQaSWx2RpakunYyPhSEe7aGXjaq7twCMy1joWsSaEXQCjqR7vaWcffdk3YDYRJxAP3zw5vKPD8tOD8djf_Xqf4Rfo0fUzQH4TYm7aLNeXpo9AEq16qMHlJ_DUUxFH20Nv6bfUjiPjs7OJ30_-dD34-QPcTkXrg
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEIIXxJ3CgIMAiSEF4kuS5gGhbTB167qHaZP6FmzHFtXapLSZ0P4Uv5Fj58Kqwd72lshWFB8f-3yffS6EvJVIfEIjbECFDQOhhAmkxtfUMMMj2teCuWjk0WE8OBH742i8Rn63sTDOrbLdE_1GnZfanZF_YoK71OS4Pr_MfwauapS7XW1LaNRqMTTnv5CyLT_vfcX5fcfY7rfjnUHQVBUIdCQYDRJrqJJRLo1E2y1VrrWKVagipXLm0qOliDCQB1hhtRI64Ynsh9aqkCuE4rnl-N0b5CYa3tCRvWTcETyOpjFtUqB6byE9m31Ee92nq0bvEpK97JB5ESh7S7d7j9xtICps1Tp1n6yZ4gG5VRetPH9ITo_KqYHSgpzmZXBqqhIWLv9rhfYQ6vMSoDAzrtIIbFN4vzU8ott0EyYFINoE7fRsAfM6QgFkkcOkWsKFQDCYl5VzYpLTR-TkWoT7mKwXZWGeEmCpSZjJVZJqZHE6V0KFOjE2pCriQrMe2Wxlmukmn7krqzHNOl6D8s-8_HvkTdd3Xmfx-GevjXZqsmYlL7O_evef5tjH6sa8R153zbhE3b2LLEx55vp4lo1Mt0ee1BPd_QWiZ85D15KsqEDXwaX_Xm0pJj98GnDEgkmcohw-eGW5YmDZ_s5o5J-eXT3EV-T24Hh0kB3sHQ6fkzvMnS14Z8cNsl4tzswLBGCVeum1Hsj3615mfwDSKUbS
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTqC9IL5XGGAESAwpLHacpnlAaN1WbSutpopJewu2Y4tqbVLaTGj_Gn8dZ-eDVYO97S2RT1F8vvP9zr4PgHcCHR9fc-NRbnyPS649ofA11kwHIe0qzmw28nDUOTzlx2fh2Rr8rnNhbFhlvSe6jTrNlT0j32E8sKXJUT93TBUWcbLf_zL_6dkOUvamtW6nUYrIQF_-Qvdt-floH9f6PWP9g297h17VYcBTIWfUi4ymUoSp0ALtuJCpUrIjfRlKmTJbKi1GtIE-geFGSa6iIBJd3xjpBxJheWoC_O4dWI-sV9SC9d7B6GRc24EADWVcFUR1sUNqNvuE1rtLV03gNVx7PTzzKmx2dq__AO5XgJXslhL2ENZ09gjuli0sLx_D-TifapIbIqZp7p3rIicLWw22QOtIytMTQslM274jpEfJh93BmPboNplkBLEnUVbqFmRe5isQkaVkUizJlbQwMs8LG9Ikpk_g9FbY-xRaWZ7pTSAs1hHTqYxihT6dSiWXvoq08akMA65YG7Zrniaqqm5um2xMk8bLQf4njv9teNvQzsuaHv-k2qqXJqn0epn8lcL_DHdc5m4naMObZhgV1t7CiEznF5bG-dzo97bhWbnQzV8glg4C345EKyLQENhi4Ksj2eSHKwqOyDDqxMiHj05YbphYcrw3HLqn5zdP8TXcQxVLvh6NBi9gg9mDBhf5uAWtYnGhXyIaK-SrSuwJfL9tTfsDW3FMbQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+aldo%E2%80%90keto+reductase+family+1+member+B1+%28AKR1B1%29+in+the+cancer+process+and+its+therapeutic+potential&rft.jtitle=Journal+of+cellular+and+molecular+medicine&rft.au=Khayami%2C+Reza&rft.au=Hashemi%2C+Seyyed+Reza&rft.au=Kerachian%2C+Mohammad+Amin&rft.date=2020-08-01&rft.issn=1582-1838&rft.eissn=1582-4934&rft.volume=24&rft.issue=16&rft.spage=8890&rft.epage=8902&rft_id=info:doi/10.1111%2Fjcmm.15581&rft.externalDBID=10.1111%252Fjcmm.15581&rft.externalDocID=JCMM15581
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1582-1838&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1582-1838&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1582-1838&client=summon